We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Abbott Diagnostics- Hematology Division

EKF Diagnostics

Manufactures analysers for the measurement of glucose, lactate, hemoglobin, hematocrit and HbA1c for GP surgeries, ph... read more Featured Products: More products

Download Mobile App


ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.
23 Sep 2021 - 25 Sep 2021

EKF Highlights Growing Product Portfolio at AACC 2014 Meeting

By LabMedica International staff writers
Posted on 28 Jul 2014
Print article
EKF Diagnostics (Cardiff, UK), a global diagnostics company, is highlighting the expanding product portfolio of its subsidiary Stanbio Laboratory (Boerne, TX, USA) at AACC 2014. EKF Diagnostics has distributors in more than 70 locations around the globe, multinational research and manufacturing facilities, and teams of experienced analysts and engineers in Germany, Ireland, USA, and the UK.

In addition to demonstrating the success of current products, including Stanbio’s ß-hemoglobin (HB) assay technology and EKF Molecular’s Pointman technology, new products will be introduced at AACC. These latest introductions result from EKF’s recent acquisition of Separation Technology Inc. (STI) and DiaSpect Medical.

The diagnostic effectiveness of Stanbio’s enzymatic Beta-Hydroxybutyrate (ß-HB) LiquiColor assay is driving its acceptance in hospital laboratories across the USA as the new standard of care in ketosis testing. More than 850 (20%) of US hospitals are now using the assay for accurate, specific, and quantitative testing of this main ketone produced during ketosis. Consequently, physicians can make better informed clinical decisions. This is changing the way hospitals manage patients displaying symptoms of ketoacidosis.

The liquid-stable LiquiColor ß-HB reagent can be used on open channel chemistry analyzers from twenty different manufacturers. A point-of-care (POC) option is also available in the form of the STAT-Site M ß-HB strip-based testing system.

Since its introduction last year, PointMan DNA enrichment technology has now been shown to be sensitive enough to enable the use of a blood sample to assess the mutation status of a cancer patient. Recent studies have demonstrated that the sensitivity of the technology is far greater than existing polymerase chain reaction (PCR) technology. PointMan can detect 1 mutant gene in 10,000 normal gene copies, whereas competing technologies can only detect 1 in 100. This maximizes the use of smaller biopsy samples and also allows the multiplexing of mutations in a single test rather than many individual tests.

To be previewed at AACC, the palm-sized DiaSpect is a fast HB measurement system giving laboratory quality performance for anemia screening in any environment. Delivering results in 1-2 seconds, the analyzer is CE marked and has been submitted to the US Food and Drug Administration (FDA; Silver Spring, MD, USA) for approval.

The PlasmaPrep-12 centrifuge is ideal for use in both the hospital and laboratory. It is designed for STAT serum/plasma separation and is suitable for coagulation studies. Enabling fast blood separation and easy to use, it is controlled by a microprocessor with four preprogrammed spin times. These include the Platelet Poor Plasma mode providing serum or plasma separations in three minutes and the Platelet Rich Plasma mode providing platelet rich plasma in just 30 seconds.

Julian Baines, CEO of EKF, commented, "EKF now offers a comprehensive and cost-effective product range, as well as meaningfully participating in personalized medicine; an area which is quickly becoming key within the IVD industry.”

Related Links:

EKF Diagnostics
Stanbio Laboratory

Gold Supplier
SARS-COV-2 PLUS UK Real Time PCR kit
Silver Supplier
Lipid Profile Analyzer
Cholestech LDX
Direct-to-PCR Workflow for SARS-COV-2 Detection
Direct to PCR SARS-COV-2 Solution
Gold Supplier
Liquid Handling Workstation
AdvanSure E3 SYSTEM

Print article



view channel
Image: The CellSearch Circulating Tumor Cell Kit is intended for the enumeration of circulating tumor cells of epithelial origin (CD45-, EpCAM+, and cytokeratins 8, 18+, and/or 19+ and PD-L1) in whole blood (Photo courtesy of CellSearch/Menarini Silicon Biosystems)

PD-L1 Expression in Circulating Tumor Cells Investigated for NSCLC

In non-small cell lung cancer (NSCLC), analysis of programmed cell death ligand 1 (PD-L1) expression in circulating tumor cells (CTCs) is a potential alternative to overcome the problems linked to the... Read more


view channel

Global Digital Polymerase Chain Reaction (dPCR) Market Projected to Reach Close to USD 1.15 Billion by 2028

The global digital polymerase chain reaction (dPCR) market is projected to grow at a CAGR of more than 9% from over USD 0.50 billion in 2020 to nearly USD 1.15 billion by 2028, driven primarily by rising... Read more
Copyright © 2000-2021 Globetech Media. All rights reserved.